RAPA 501 EAP

The RAPA-501-ALS Expanded Access Program (EAP) is recruiting people living with ALS who are no longer eligible for clinical trials. The clinical research team can help you determine your eligibility.

RAPA-501 is a cell therapy that is thought to protect motor neurons from inflammation. This study is open-label, which means everyone involved knows what treatment is being given, and non-randomized, so there’s no chance of getting a placebo.

Study participation includes 7 in-person visits, (screening, apheresis, 4 dosing visits, and 1 follow-up visit), and 2 remote follow-up visits.

Enrollment Contact:
Lupita Rodriguez
602-406-6641
Fulton.Research@CommonSpirit.org